Bionovo's VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company's second estrogen receptor beta selective drug candidate that will be entering clinical trials shortly.
Source: www.medicalnewstoday.comPatient Focus As A Key Success Factor In The Treatment Of Atopic Dermatitis Atopic dermatitis (AD) is a chronic inflammatory pruritic skin disease that affects many children and adults, often significantly compromising their quality of life. Treatment success, therefore, should be considered not only from a clinical point of view but also from the patient's perspective.
Source: www.medicalnewstoday.comConcert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial - Potential Best-in-Class Non-Hormonal Treatment For Vasomotor Symptoms Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in
healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
Source: www.medicalnewstoday.comNovartis' Once Daily Iron Chelator, Exjade(R) (deferasirox) Awarded Prestigious UK Prix Galien Medicines Prize Exjade (deferasirox) has been awarded a prestigious Prix Galien award for innovative research and development in orphan
drugs. The once-daily oral iron chelator from Novartis treats patients with transfusion iron overload. Novartis' new anti-cancer targeted agent, Tasigna (nilotinib) was also commended by judges, including Sir Michael Rawlins of National Institute for
Health and Clinical Excellence.
Source: www.medicalnewstoday.comDebiopharm Moves Towards A New 6-Month Formulation Of Decapeptyl(R) To Further Help Prostate Cancer Patients Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Source: www.medicalnewstoday.comTyverb® Demonstrates Encouraging Results In Phase II Study In Advanced Head And Neck Cancer GlaxoSmithKline's (GSK) oral targeted agent Tyverb® (lapatinib) demonstrated single agent activity and improvement in clinical response to the subsequent standard chemoradiation compared to placebo in a Phase II study of advanced squamous cell carcinoma of the head and neck (SCCHN).
Source: www.medicalnewstoday.comCutting Edge Information Study Finds Pharma Pricing Research Being Conducted Earlier Pharmaceutical and biotech companies conduct pricing research much earlier in drug development than they once did. The new study, "Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs," published by competitive intelligence firm Cutting Edge Information, finds that 56% of companies begin pricing-focused market research before Phase III of product development (http://www.
Source: www.medicalnewstoday.comBoston Scientific Announces FDA Approval Of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels Boston Scientific Corporation (NYSE: BSX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. No other DES for sale in the U.S.
Source: www.medicalnewstoday.comAnalysis Of Earlier European Stroke Trial Supports Treatment Regimen For Viprinex(TM) In Current International Phase 3 Clinical Trials Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic stroke may be minimized with avoidance of prolonged low levels of fibrinogen and use of common blood pressure entry criteria.
Source: www.medicalnewstoday.comFive Year Data Confirm That Early Treatment With Betaferon® At First Sign Of Disease Can Delay Progression To MS New data confirm that early initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) significantly delays the onset of clinically-definite MS (CDMS) by 37 percent (p=0.003) and McDonald MS by 45 percent (p
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
